TT-232

Somatostatin Analogue / HeptapeptideRx: ResearchCompound: Investigational

Also known as: Anticancer somatostatin heptapeptide, D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2, TT232

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

TT-232 is a synthetic heptapeptide analogue of somatostatin developed primarily as an anticancer agent. Unlike classical somatostatin analogues, it exerts potent antiproliferative and pro-apoptotic effects on tumor cells with minimal hormonal (antisecretory) activity. It has been investigated in preclinical and early clinical studies for solid tumors.

Mechanism of Action

Binds to somatostatin receptors (primarily SSTR4) and activates intrinsic apoptotic pathways in tumor cells; inhibits cell proliferation via caspase activation and modulation of tyrosine kinase signaling without significant endocrine effects.

Routes of Administration

IntravenousSubcutaneous

Goals & Uses

  • Induction of tumor cell apoptosisOncologyModerate
  • Solid tumor treatmentOncologyLow
  • Neuroendocrine tumor managementOncologyLow
  • Antiangiogenic effectOncologyLow

Contraindications

  • Severe hepatic impairmentOrganModerateLiver function concerns
  • Known hypersensitivity to somatostatin analoguesAllergyHigh
  • PregnancyPopulationHighPotential fetal risk or insufficient safety data

Adverse Effects

  • HypoglycemiaMetabolicRareAbnormally low blood glucose
  • Injection site reactionsLocalCommon
  • NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
  • FatigueGeneralUncommonLow energy or tiredness

Drug Interactions

  • Chemotherapeutic agentsModerate
  • Insulin / Oral hypoglycemicsLow

Population Constraints

  • Pediatric patientsAgeRelative
  • Pregnant or lactating womenReproductiveRelative
  • Patients with severe renal impairmentOrgan ImpairmentRelative

Regulatory Status

  • European UnionInvestigationalPhase I/II clinical investigations conducted in Hungary; no EMA marketing authorization.
  • United StatesInvestigationalNot FDA-approved; no IND filing publicly confirmed; research compound only.
  • United KingdomUnknownNo MHRA approval; status mirrors EU investigational classification.

No approved indications in any major jurisdiction. Investigated in Phase I/II clinical trials in Europe (particularly Hungary). Not FDA-approved. Orphan or special research-use designations may apply in some contexts.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack